U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 23:32:04 GMT 2025
Edited
by admin
on Mon Mar 31 23:32:04 GMT 2025
Protein Type TRANSPORTER
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
B46KUN2O9L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MATE-2
Common Name English
FLJ31196
Preferred Name English
MATE-2K
Common Name English
SLC47A2
Common Name English
HMATE-2K
Common Name English
SOLUTE CARRIER FAMILY 47 MEMBER 2
Common Name English
HMATE-2
Common Name English
MATE2
Common Name English
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2
Common Name English
MATE2-K
Common Name English
Classification Tree Code System Code
UCSF-FDA TRANSPORTAL SLC47A2
Created by admin on Mon Mar 31 23:32:04 GMT 2025 , Edited by admin on Mon Mar 31 23:32:04 GMT 2025
Code System Code Type Description
WIKIPEDIA
SLC47A2
Created by admin on Mon Mar 31 23:32:04 GMT 2025 , Edited by admin on Mon Mar 31 23:32:04 GMT 2025
PRIMARY
FDA UNII
B46KUN2O9L
Created by admin on Mon Mar 31 23:32:04 GMT 2025 , Edited by admin on Mon Mar 31 23:32:04 GMT 2025
PRIMARY
UNIPROT
Q86VL8
Created by admin on Mon Mar 31 23:32:04 GMT 2025 , Edited by admin on Mon Mar 31 23:32:04 GMT 2025
PRIMARY
Related Record Type Details
Structure of CIMETIDINE
INHIBITOR -> TRANSPORTER
Structure of GLASDEGIB
INHIBITOR -> TRANSPORTER
Structure of TALIPEXOLE
INHIBITOR -> TRANSPORTER
Structure of CETIRIZINE
INHIBITOR -> TRANSPORTER
Structure of N-BUTYLPYRIDINIUM CHLORIDE
INHIBITOR -> TRANSPORTER
Structure of Cabozantinib
INHIBITOR -> TRANSPORTER
IC50
Structure of FAMOTIDINE
INHIBITOR -> TRANSPORTER
Structure of PROPANAMIDE, N-(5-(2-(2-METHOXY-3-PYRIDINYL)-7-METHYLIMIDAZO(1,2-A)PYRIDIN-3-YL)-6-(2-(1-METHYL-6-ISOQUINOLINYL)ETHYNYL)-2-PYRIDINYL)-2-(METHYLAMINO)-, (2S)-
INHIBITOR -> TRANSPORTER
Structure of RANITIDINE
INHIBITOR -> TRANSPORTER
Structure of Guanidine
SUBSTRATE -> TRANSPORTER
Structure of DESIPRAMINE
INHIBITOR -> TRANSPORTER
Structure of TETRAETHYLAMMONIUM
SUBSTRATE -> TRANSPORTER
Structure of DILTIAZEM
INHIBITOR -> TRANSPORTER
Structure of DM-3411
INHIBITOR -> TRANSPORTER
Structure of LEVOFLOXACIN ANHYDROUS
INHIBITOR -> TRANSPORTER
Structure of AMPHETAMINE
SUBSTRATE -> TRANSPORTER
Structure of AMANTADINE
INHIBITOR -> TRANSPORTER
Structure of DX-619
INHIBITOR -> TRANSPORTER
Structure of AMISULPRIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of ACYCLOVIR
SUBSTRATE -> TRANSPORTER
Structure of CIPROFLOXACIN
INHIBITOR -> TRANSPORTER
Structure of RUCAPARIB
INHIBITOR -> METABOLIC ENZYME
Structure of CYPERQUAT
SUBSTRATE -> TRANSPORTER
Structure of SOTORASIB
INHIBITOR -> TRANSPORTER
IC50
Structure of IMIPRAMINE
INHIBITOR -> TRANSPORTER
Structure of PROPANAMIDE, N-(5-(2-(2-METHOXY-3-PYRIDINYL)-7-METHYLIMIDAZO(1,2-A)PYRIDIN-3-YL)-6-(2-(1-METHYL-6-ISOQUINOLINYL)ETHYNYL)-2-PYRIDINYL)-2-(METHYLAMINO)-, (2S)-
NON-SUBSTRATE -> TRANSPORTER
Structure of DIPHENHYDRAMINE
INHIBITOR -> TRANSPORTER
Structure of Olaparib
INHIBITOR -> TRANSPORTER
Structure of Metformin
INHIBITOR -> TRANSPORTER
Structure of Ganciclovir
SUBSTRATE -> TRANSPORTER
Structure of METHAMPHETAMINE
SUBSTRATE -> TRANSPORTER
Structure of TOPOTECAN
SUBSTRATE -> TRANSPORTER
Structure of GILTERITINIB
INHIBITOR -> TRANSPORTER
WEAK
Structure of PROCAINAMIDE
INHIBITOR -> TRANSPORTER
Structure of Metformin
SUBSTRATE -> TRANSPORTER
Structure of Apalutamide
INHIBITOR -> TRANSPORTER
Structure of TAFENOQUINE
INHIBITOR -> TRANSPORTER
corrected for non-specific binding
IC50
Structure of COBICISTAT
INHIBITOR -> TRANSPORTER
Structure of Risdiplam
INHIBITOR -> TRANSPORTER
IN VITRO
Structure of Pralsetinib
INHIBITOR -> TRANSPORTER
Structure of Rifamycin
INHIBITOR -> TRANSPORTER
Rifamycin is an inhibitor of renal transporters organic anion transporter (OAT) 3, multidrug and toxin extrusion (MATE) 1, and MATE2-K transporters in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant inhibition of these transporters in vivo is unlikely.
Structure of VERAPAMIL
INHIBITOR -> TRANSPORTER
Structure of CHLORPHENIRAMINE
INHIBITOR -> TRANSPORTER
Structure of METHAMPHETAMINE
INHIBITOR -> TRANSPORTER
IC50
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
INHIBITOR -> TRANSPORTER
IC50
Structure of ESTRONE SULFATE
SUBSTRATE -> TRANSPORTER
Structure of Tirbanibulin
INHIBITOR -> TRANSPORTER
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MATE2-K
IC50
Structure of DISOPYRAMIDE
INHIBITOR -> TRANSPORTER
Structure of IMEGLIMIN
SUBSTRATE -> TRANSPORTER
Structure of QUINIDINE
INHIBITOR -> TRANSPORTER
Structure of FEDRATINIB
INHIBITOR -> TRANSPORTER
IC50
Structure of BRANEBRUTINIB
INHIBITOR -> TRANSPORTER
Structure of AMISULPRIDE
INHIBITOR -> TRANSPORTER
Structure of COPANLISIB
INHIBITOR -> TRANSPORTER
Structure of PROCAINAMIDE
SUBSTRATE -> TRANSPORTER
Structure of CIMETIDINE
SUBSTRATE -> TRANSPORTER
Structure of PRAMIPEXOLE
INHIBITOR -> TRANSPORTER
Structure of PLAZOMICIN
INHIBITOR -> TRANSPORTER
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966